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Abstract
The field of clinical proteomics offers opportunities to
identify new disease biomarkers in body fluids, cells
and tissues. These biomarkers can be used in clinical
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applications for diagnosis, stratification of patients for
specific treatment, or therapy monitoring. New pro-
tein array formats and improved spectrometry tech-
nologies have brought these analyses to a level with
potential for use in clinical diagnostics. The nature of
the human body fluid proteome with its large dynam-
ic range of protein concentrations presents problems
with quantitation. The extreme complexity of the pro-
teome in body fluids presents enormous challenges
and requires the establishment of standard operating
procedures for handling of specimens, increasing
sensitivity for detection and bioinformatical tools for
distribution of proteomic data into the public domain.
From studies of in vitro diagnostics, especially in clin-
ical chemistry, it is evident that most errors occur in
the preanalytical phase and during implementation of
the diagnostic strategy. This is also true for clinical
proteomics, and especially for fluid proteomics
because of the multiple pretreatment processes.
These processes include depletion of high-abundance
proteins from plasma or enrichment processes for
urine where biological variation or differences in pro-
teolytic activities in the sample along with preanaly-
tical variables such as inter- and intra-assay variability
will likely influence the results of proteomics studies.
However, before proteomic analysis can be intro-
duced at a broader level into the clinical setting, stan-
dardization of the preanalytical phase including
patient preparation, sample collection, sample prep-
aration, sample storage, measurement and data anal-
ysis needs to be improved. In this review, we discuss
the recent technological advances and applications
that fulfil the criteria for clinical proteomics, with the
focus on fluid proteomics. These advances relate to
preanalytical factors, analytical standardization and
quality-control measures required for effective imple-
mentation into routine laboratory testing in order to
generate clinically useful information. With new dis-
ease biomarker candidates, it will be crucial to design
and perform clinical studies that can identify novel
diagnostic strategies based on these techniques, and
to validate their impact on clinical decision-making.
Clin Chem Lab Med 2009;47:724–44.
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Introduction
The proteome of an organism, as the complement of
its genome, is highly dynamic and varies according
to cell type and functional state. These effects in pro-
tein composition may be observed in body fluids and
may reflect immediate and characteristic changes in
response to disease processes and external stimula-
tion. Clinical proteomics is the field that encompasses
the quantitative and qualitative profiling of proteins
and peptides that are present in clinical specimens
like tissues and body fluids. The actual proteome
present in body fluids, cells and tissues at a certain
point of time cannot be directly predicted from
genomic information because, it represents only a
subset of all possible gene products. Proteins may
exist in multiple forms within cells or between various
cells due to post-translational modifications (PTMs) or
degradation processes that affect protein structure,
function, localization and turnover. It is possible that
in addition to the proteome, proteolytic degradation
products, termed low-molecular-weight (LMW) range
proteome, also may contain disease-specific infor-
mation and lead to the identification of disease-
specific biomarkers. Disease-specific peptides often
appear as fragments of endogenous high-abundant
proteins (e.g., transthyretin), or fragments of low-
abundance cellular and tissue proteins, such as
BRCA-2 (breast cancer) (1, 2). In addition, the extent
of degradation of proteins by catabolic pathways may
depend on preanalytical variables like temperature or
time of storage of the sample. Therefore, special care
must given to specimen handling.
Our ability to identify and characterize molecules
for early detection of disease or stratification of dis-
ease and to expand the prognostic capability of cur-
rent proteomic modalities is enhanced by emerging
novel nanotechnology strategies that make use of
these LMW biomarkers in vivo or ex vivo. However,
they may also lead to new problems related to accu-
racy and variation. Pathophysiological processes that
involve proteolytic activities such as tumor proteases,
are detectable in the plasma peptidome (1). The iden-
tification and characterization of highly specific and
sensitive proteins or biomarker panels for risk strati-
fication, prognostic assessment or early detection of
disease is the key to treatment of complex diseases
such as cancer, neurodegenerative disorders and
metabolic and vascular disease.
The focus of clinical proteomics is on the analytical
and clinical validation and implementation of novel
diagnostic or therapy related markers identified in
preclinical studies such as, for example, drug screen-
ing studies. Clinical proteomics, with an emphasis on
fluid proteomics, also includes the selection, valida-
tion, and assessment of standard operating proce-
dures (SOPs) in order that adequate and robust
methods are integrated into the workflow of clinical
laboratories. Standard measures need to be intro-
duced in order to protect specimens from cell lysis,
non-specific proteolysis and modification during col-
lection, transport, and preparation prior to analysis.
Useful considerations of preanalytical variables con-
cerning body fluids are reported in the review of Paik
et al. (3).
Selection of potential targets for clinical proteomics
follows either a top-down or a bottom-up approach.
The top-down approach applies high-throughput
technologies to either population-based studies or
selected cohorts, such as case/control studies or twin
registers, in order to identify novel markers using an
unbiased approach. These makers have to be further
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characterized with respect to sensitivity, specificity,
and function. The bottom-up approach focuses on
previously identified pathways and looks for protein-
protein or metabolite interactions, or interactions
related to the pathway.
Recent advances in proteomic analysis due to use
of high-throughput and high-content analysis has
paved the way for clinical proteomics. These advanc-
es have been realized in the field of affinity binder
technologies and in liquid phase technologies such as
tandem mass spectrometry (MS/MS). For fluid proteo-
mics, Luque-Garcia and Neubert have reviewed and
summarized sample preparation for profiling and bio-
marker identification using mass spectrometry (MS)
(4). High-resolution liquid phase separation methods,
along with advances in chemometry and biometry for
large-scale data analysis, now, offer the possibility for
introducing these tools into laboratory diagnostics.
This will enable screening for risk factors, identifica-
tion of new disease-specific or stage-specific biomar-
kers and identification of novel markers for thera-
peutic drug monitoring or new therapeutic targets.
Clinical proteomics has the potential to complement
genomics, metabolomics, lipidomics, glycomics and
transcriptomics, including splice variant analysis, and
to contribute to a better understanding of disease
processes. This will enable translation of this complex
knowledge into diagnostic tools for clinicians.
Clinical proteomics is now on the verge of entering
the hospital, similar to the field of metabolomics,
which has now been established for clinical diagnosis
in newborn screening. However, before this occurs,
essential criteria for successful use in a clinical envi-
ronment need to be fulfilled. First, it is crucial that
high-throughput analytical platforms be implemented
that provide reproducible protein patterns with a clin-
ically acceptable turnaround time. Also, they need to
be robust enough for everyday use, simple enough to
be operated by technicians with a minimum of super-
vision required, and be able to fit into the clinical
laboratory workflow. Second, bioinformatic algo-
rithms need to be developed that include chemome-
try, data reduction and conversion into actionable
health information. These algorithms also must be
robust and easily integrated into current laboratory
information systems. Third, the preanalytical condi-
tions for clinical specimens need to be standardized
and optimized for the development of clinically appli-
cable tests. Prior to research on the development of
novel biomarkers, appropriate and well-defined
patient cohorts that address a specific clinical ques-
tion need to be selected. These cohorts should be
well-characterized by appropriate anamnestic and
physiologic parameters including age, sex, hormonal
status, treatment and hospitalization status. This
information should be made available for study. Fur-
thermore, SOP-driven biobanks and biorepository
systems have to be established and integrated into
the diagnostic workflow and storage conditions
should be validated. Undoubtedly standardized and
SOP-driven preparation of patient samples for body
fluid proteomics, like any other clinical laboratory
analysis, is one of the most urgent challenges for
obtaining reproducible and clinical useful results. Fur-
thermore, regulations must be established to address
medico-legal issues such as patient consent and com-
mercial use of samples, as well as intellectual prop-
erty. This must be achieved at a supra-national level
to allow for large-scale multi center studies, which are
a prerequisite for the task at hand.
In this review, we focus on fluid proteomics and
suggest procedures for sample preparation and stan-
dardization of protocols for analysis of body fluids.
We summarize the preparative and analytical meth-
ods in the field and emphasize key clinical applica-
tions. We conclude with bioinformatic approaches in
proteomics. Another review focusing on cellular pro-
teomics (cytomics) is being prepared as a consensus
document from the authors and will follow.
Preanalytical phase
It is well known that sources of technical or sample
variation are found primarily in the preanalytical
phase. Lack of standardized procedures for patient
preparation (e.g., fasting, diurnal rhythm), specimen
acquisition, handling, and storage account for more
than 90% of the errors within the entire diagnostic
process (5). Advances in genomics and proteomics
have led to high expectations for clinical biomarker
discovery and use. For successful generation of vali-
dated biomarkers, more attention has to be focused
on the preanalytical stage in areas such as sample
collection, transport, preparation, and processing (6).
In addition, standardization and quality management
procedures, in particularly when large biorepositories
(biobanks) are being established and used, need to be
addressed. The preclinical discovery phase will target
promising biomarkers that require validation before
translation into clinical proteomics can occur. The
type of sample needed, as well as sample processing,
could be quite different for the different phases of bio-
marker development and biomarker validation. There
is a considerable difference between the require-
ments for high-throughput proteomic profiling for
clinical proteomics, and subsequent protein identifi-
cation and in-depth characterization of single protein
samples (low-throughput) in the preclinical and dis-
covery phase. It is well known that individual clinical
chemistry and hematology parameters are prone to
significant influence by preanalytical handling of
biological fluids. It is very likely that proteomic pro-
files consisting of a plethora of individual parameters
will also be susceptible to preanalytical handling.
Among the plethora of possible variables from
which preanalytical effects can arise are the site of
sample collection, the process of blood collection, the
material and liquid content of the sample container,
the time until sample processing and the temperature
(7).
Cerebrospinal fluid (CSF) parameters such as pro-
tein composition and total protein content vary sig-
nificantly depending of the site of sample collection,
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as for example from the ventricles obtained during
surgery or by lumbal puncture. Also, the site used for
collection of blood samples is important (8). In vitro
hemolysis causing leakage of hemoglobin and other
intracellular erythrocyte components into the blood
fluid can occur when blood is collected from fragile
veins such as hand veins instead of veins in the ante-
cubital area. Hemoglobin interferes with a variety of
analytical reactions and causes an increase in absor-
bance measurements, especially at 415, 540 and
570 nm (9–15). Even if hemolysis is not visible, hemo-
globin chains can be detected on polyacrylamide gels
and occur as characteristic peaks on matrix assisted
laser desorption/ionization (MALDI) or surface-
enhanced laser desorption/ionization (SELDI) spectra
(16, 17). It can be concluded that hemolysis might
have a significant impact on identification of proteo-
mic parameters and, therefore, should be avoided.
Another intracellular molecule in erythrocytes that
can interfere with laboratory tests is adenylate kinase.
This molecule interferes with the determination of
creatin kinase and causes falsely increased results.
The time of sample collection is also a preanalytic
factor not to be underestimated (18). Many para-
meters such as peptide hormones and cytokines have
diurnal rhythms. For the collection of urine, consid-
eration must also be given to the time that urine is
stored in the urinary bladder prior to collection. It has
been shown that first void morning urine is more
prone to protein degradation because of bacterial
contamination, compared with urine collected at
other times (19). In addition, significant differences in
proteomic profiles of urine determined by surface-
enhanced laser desorption/ionization time-of-flight
mass spectrometry (SELDI-TOF-MS) were document-
ed to be dependent on the collection time (20). The
greatest differences seem to occur between urine col-
lected at midday and the first and second morning
urine. One should also keep in mind the importance
of patient preparation as, for example, parameters
that depend on metabolic status where fasting before
sample collection is essential.
Only a few studies have been performed that dem-
onstrate the effects that sample collection procedures
have on proteomic profiling; handling and storage
had comparably lower effects (16).
Another important issue that impacts determination
of certain parameters is the mode of specimen collec-
tion. Needle bore size, patient posture and tourniquet
application have a significant effect on parameters
such as total protein, albumin, IgGs or erythrocyte
integrity (21–23). The type of sample container influ-
ences parameter results. Serum and plasma differ as
a consequence of clotting. In addition to the reduction
in proteins and fibrinogen due to the clotting cascade,
many other differences have been documented. Gen-
erally there are more peptides in serum, but the type
of anticoagulant also influences the peptide compo-
sition (16, 24–27). Complement C3f, for example, is
released by factors I and H and is a fragment of com-
plement C3b, a cleavage product of complement C3
(28). Complement C3f was found in higher concentra-
tions in serum than plasma (29), indicating that the
full-length peptide is generated by a post-coagulation
exoprotease. The clotting time also has a significant
influence on parameter results. It has been observed
that the intensity of protein peaks determined by
SELDI-TOF changes significantly during clotting of
serum from 30 min to 60 min (30). After 60 min,
changes could only be documented if the sample was
stored at room temperature, but not if the sample was
stored on ice. This study indicates that serum should
be prepared 60 min following clotting at room tem-
perature, followed by storage at 48C or even better at
–808C before analysis.
Tube and anticoagulant type can also influence
sample processing. EDTA chelates divalent cations
and, therefore, is not suitable for assays dependent
on such ions. Highly charged heparin molecules may
interact with proteins and alter their separation char-
acteristics when using chromatography (27). If hepa-
rin is used as the anticoagulant, dilution effects have
to be taken into consideration, especially if the tube
is not filled completely. Tubes containing a gel-based
separator can alter sample composition. It is not
known whether this alteration is caused by effects on
the clotting cascade or by effects of the gel itself on
the proteins (16, 27). For b-amyloid and t-protein
determination in CSF, the tube material has to be
chosen carefully. CSF should not be collected in poly-
styrene, but rather in polypropylene tubes (31) to pre-
vent erroneous results. On the other hand, substances
released from the material, e.g., polyvinylpyrrolidone
(PVP), can have a direct impact on MALDI-TOF spectra
by generating multiple interfering peaks in the m/z
range of 1000–3000 (32). Polymers from different
brands of tubes and heparin have been described as
inducing ion suppression effects (33).
Processing temperature, elapsed time following
venipuncture before separation of plasma or serum
from cells and centrifugation speed and duration may
have a significant impact on parameter results. The
duration between post-venipuncture and sample
processing may cause different stages of coagulation
and complement processes, or the release of cell-
derived products, and influence parameter results (16,
24, 25, 34).
The effects of temperature are ambiguous. Low
temperature minimizes proteolytic activity. However,
blood samples also contain various antiproteases,
therefore, cooling may not be necessary. In addition,
for some analytes such as platelets, it is recommend-
ed that samples are processed at 18–208C to prevent
platelet activation. This could also have an effect on
the plasma proteome, especially, for small proteins.
Erythrocytes are less stable at lower temperatures.
Therefore, release of intra-erythrocytic proteins into
the plasma is more likely due to hemolysis.
Proteolysis can also continue in frozen samples.
Differences between samples frozen for 1–3 months
at –208C or –808C have not been observed in several
studies (16, 26, 34). However, this may be due to the
short storage times because another research group
reported that most differences became apparent after
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about 5 months of storage (35). One peptide noted to
be altered by storage at low temperature was a bio-
marker previously identified as a candidate for colo-
rectal cancer, an N-terminal albumin fragment (m/z
3087). This underlies the importance of correct prea-
nalytic handling to prevent false results. Another pro-
tein influenced by storage conditions is complement
C3f, discussed above. The corresponding peak was
seen in samples frozen at –208C for -1 month, but
not in samples stored at –708C (35). Since there was
a higher C3f concentration when stored at –208C, it is
likely that the exoprotease continues to generate C3f
at low temperature storage conditions. In addition to
serum and plasma proteins and peptides being affect-
ed by storage, proteins of diagnostic relevance col-
lected from CSF are also affected. It has been shown
that cystatin C, a LMW cysteine proteinase inhibitor,
is cleaved with the resulting loss of its N-terminal
amino-acids when stored for 3 months at –208C, but
not at –708C (36). If not considered, such issues can
lead to incorrect conclusions. A recent study using
SELDI-TOF on CSF from patients with multiple scle-
rosis proposed that a unique 12.5 kDa protein peak,
reportedly a C-terminally cleaved cystatin C isoform,
enabled distinction of multiple sclerosis from other
neurological diseases with 100% specificity (37). How-
ever, a later study showed that this result was a stor-
age related artefact and not useful as a diagnostic
marker for multiple sclerosis (38). The 12.5 kDa cys-
tatin C isoform was produced from full-length cystatin
C during storage at –208C.
However, proteolytic cleavage that occurs following
blood collection could also reflect disease-specific
protease activities, and, therefore be the result of a
particular disease such as cancer (29). It was shown
that fragments observed after sample storage at
–208C still allow discrimination of colorectal cancer
patients and healthy controls (35).
Another important issue that is very likely to alter
parameter results are freeze-thaw cycles, although
the effects have not been investigated systematically
by many groups. In one systematic investigation, sera
of eight patients with sarcoidosis and eight controls
were frozen and then thawed between one and eight
times and then spotted on a CM10 (cation exchange)
and on a NP20 (normal phase) ProteinChip array (39).
Three different peaks distinguishing patients and con-
trols could be identified in the samples frozen and
then thawed more frequently. In contrast, using fresh-
ly frozen sera, none of these markers, except for
another significant single peak, was identified. These
results indicate the importance of avoiding freeze-
thaw cycles.
To address preanalytical effects on parameter
results, standard protocols for serum and plasma
sampling, handling and storage are required. This
necessity does not arise from the issue of which pro-
cedure is better, but rather standardized procedures
need to be used in order to obtain comparable and
reproducible results between different laboratories or
research groups (26).
Standardization of the (pre)analytical process
To achieve reproducible clinical proteomics results,
standardization is an essential requirement. The
importance of standardization is demonstrated by
three different studies on prostate cancer which found
completely different decision trees using identical
chip types and comparable study populations (40–42).
Examples of systematic bias errors resulting in
false-positive and false-negative results include 1)
preanalytical variables such as systematic differences
in study populations and/or sample collection, han-
dling, and pre-processing procedures; 2) within-class
biological variability which may comprise unknown
sub-phenotypes among study populations; 3) analyt-
ical variables such as inconsistencies in instrument
conditions and reagents which result in poor repro-
ducibility, and 4) measurement imprecision (18, 43).
To minimize these effects and to allow a compari-
son among different clinical studies, researchers and
clinicians need to standardize and clearly describe the
protocols used and the performance of clinical stud-
ies. The study aims have to be clearly defined,
patients and controls have to be accurately character-
ized, the samples that are collected, the collection pro-
cedures, the sample preparation and processing
methods and data modeling algorithms have to be
carefully documented. For example, with respect to
the characterization of patients and controls, one
interesting question is whether controls should con-
sist not only of healthy individuals, but also of
patients suffering from another disease affecting the
same organ or producing the same symptoms. The
latter case is clinically more interesting because it
aims to identify biomarker panels suited for differen-
tial diagnosis instead for the identification of sick indi-
viduals. But for this approach a detailed description
of the controls is needed, rather than just referring to
them as the control group. Existing standardization
protocols with good reputation, for example the stan-
dard of ‘‘good clinical practice’’ (GCP) (See European
Union Directive 2001/20/EC) and the ‘‘good clinical
laboratory practice’’ (GCLP) (7) should be utilized for
clinical proteomic studies.
The effects of preanalytical variation and the need
to standardize the preanalytical phase is highlighted
by Marshall et al. (44). Using MALDI-TOF-MS, these
authors analyzed blood samples obtained from
patients with myocardial infarction and found that
recorded changes in the protein profiles correspond-
ed to serum protease activities, rather than being the
result of disease processes.
Following identification of a single biomarker or a
biomarker panel, a clear definition of the protein(s),
including sequence and PTMs is mandatory as part of
the standardization process. However, since many
standard methods such as those for MS/MS applica-
tions do not consider PTMs, it is necessary to accu-
rately document the physico-chemical properties
necessary for detection of the identified biomarker.
The physico-chemical properties also have to be doc-
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umented since they can significantly influence the
results. For example, they can influence the dynamic
range and sensitivity of the applied method as dem-
onstrated by the stains used on protein gels and their
differences in dynamic range and sensitivity of pro-
tein quantification. For instance, in contrast to the
older Coomassie blue and silver stains, the newer flu-
orescent stains have a higher dynamic range and a
similar sensitivity (45).
With quality control, standardization should also
include the acceptable deviation for identical analytes
detected in different samples. Proteome data are
always prone to error, but the extent needs to be
detected and thresholds defined.
Standardization does not end after a study is per-
formed and data collected, but should also include
data storage. For multivariate analyses like proteo-
mics, a huge amount of data is necessary. To allow
the comparison and further development of different
proteomic investigations it is necessary to store pro-
teomic data in a standardized data format using very
exact and precise rules. Apart from the final results,
this database should also include all information
about the study protocol, patient and control pheno-
typing, sample collection and processing, quality
control criteria, calibration and matching.
Another source of variation to be considered in bio-
marker discovery is the heterogeneity of the human
population (biological variation), referred to as
between-subject variation. Between-subject variation
is the sum of differences in protein expression
between people resulting in, but not limited to, differ-
ences in age, gender, or race (46). Of course, this kind
of biological variation cannot be avoided but has to
be taken as a fact and considered in the analytical
proteomic strategy as well as in interpretation of
results.
The use of control materials, e.g., the addition of
standards, is mandatory for controlling the linear
range, specificity, sensitivity, precision, and accuracy.
Once the instrument is calibrated, standardization of
the output can be accomplished by running control
samples and adjusting parameters such as laser
intensity, detector voltage, and detector sensitivity to
ensure that spectra are consistent between runs. Con-
trols, either as internal or added analytes, should also
be analyzed throughout an experimental run; the
former is preferable, if possible, as internal controls
would not interfere at all with the analytical process.
A recent study using SELDI-TOF on prostate cancer
cases and control cases demonstrated that implemen-
tation of such strategies on SELDI-TOF approach may
provide reproducible results for peak patterns (47).
However, other issues for this approach need to be
discussed further. Transition of MS technology from
a research tool to a reliable clinical diagnostic plat-
form requires rigorous chemometric standardization,
spectral quality control and assurance, SOP for robo-
tic and automatic sample application, and standard-
ized controls to ensure the generation of highly
reproducible spectra. The introduction of peptide
standards at defined quantities, as well as the use of
quantitative labeling techniques (e.g., stable isotope
labeling) for routine applications, may eventually
allow quantitative assessment of selected markers.
Currently, laboratories are independently developing
their own methods, optimization procedures and in-
process controls, but effort is lacking for standard-
izing methods between laboratories. Current
instrumentation is at the level of ‘‘advanced proto-
types’’ that provide research tools for specialized lab-
oratories, but do not yet qualify for routine laboratory
testing. However, the development of standard tech-
nologies for MS platforms with reference standards
for controls and calibrators will certainly help to accel-
erate the process of evaluating proteomics technolo-
gies for clinical applications. This transition will
require widespread collaborative efforts between
public health organizations, legislation, industry,
researchers, healthcare providers, health insurance
companies and patient organizations.
With advances in analytical instrumentation and
reagent quality, and the availability of high-quality
analytical standards, analytical errors are no longer
the primary factors influencing the reliability and clin-
ical utilization of laboratory diagnostics. An example
of a standardized protocol for sampling and prepara-
tion of blood as established by the National biobank
program in Sweden can be found at http://
www.biobanks.se (SOP – Collection of blood samples
Gerd Johansson Go¨ran Hallmans, Medicinska
biobanken).
Proteomics in body fluids
Techniques for proteomic analysis
The techniques used for protein analysis can gener-
ally be divided into ‘‘unbiased’’ and ‘‘biased’’ meth-
ods. In ‘‘unbiased’’ techniques, the investigator does
not preselect the proteins to be examined, but search-
es for changes in any proteins that are identified.
Such methods typically include multiple protein sep-
aration techniques such as 2-dimensional sodium
dodecylsulfate polyacrylamide gel electrophoresis
(2D-PAGE) and SELDI-TOF. Protein subpopulations
are enriched according to their physico-chemical or
immunological characteristics by binding to a variety
of modified chip surfaces prior to MALDI-TOF-MS
(‘‘SELDI-TOF’’ MS), liquid chromatography (LC) meth-
ods where the protein mix flows through a column
packed with porous beads of particular binding prop-
erties, and capillary electrophoresis (CE) where pro-
teins are separated based on their charge dependent
migration in an electric field. These separation strat-
egies are followed by protein identification using
MALDI-TOF-TOF or electrospray ionization tandem
mass spectrometry (ESI-MS-MS). ‘‘Biased’’ tech-
niques include antibody-based affinity-binding meth-
ods or multiple reaction monitoring tandem mass
spectrometry (MRM-MS-MS), where the proteins of
interest have already been identified. Highly specific
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antibodies against these proteins or specific peptides
are synthesized and labeled. This allows for more in
depth profiling of these preselected proteins, enabling
protein abundance to increase by more than eight
orders of magnitude.
2D-PAGE The first technique used for separation in
proteomics is often 2D-PAGE. With this technique,
proteins are separated both according to their isoe-
lectric point (pI) and mass (combination of isoelectric
focusing and SDS-PAGE). The resolution power of 2D-
PAGE allows the identification of 1000–2000 protein
spots. In theory, it is possible to visualize up to 10,000
protein spots in a single large gel (48). To achieve
higher resolution and to improve the detection of low-
abundance proteins, several 2D-GE can be used with
overlapping narrow pH gradients which helps reduce
the amount of protein/spot (49–51). Proteins can be
visualized using Coomassie brilliant blue or silver
nitrate, or by the use of a sample pre-labeled with
fluorescent dyes such as SYPRO Ruby and cyanine
dyes (Cy2, Cy3, Cy5) (40, 45, 52–54). The use of fluo-
rescent dyes increases sensitivity, offers a linear
dynamic range exceeding up to three orders of mag-
nitude and allows for quantitative comparison of
gel-based protein patterns (55, 56).
Post-translational protein modifications that alter
the pI or the overall molecular mass can be identified
by changes in the x/y position within the 2D gel. Since
changes of a single charge are detectable with this
technique, the effects of post-translational processing
such as differently phosphorylated or glycosylated
forms of the same protein can be identified as a series
of spots having the same molecular weight (57–59).
Spots of interest can be excised and subjected to pro-
teolytic digestion. The resulting peptides are then
analyzed by MALDI-TOF-MS or LC-MS and compared
with theoretical spectra from databases to identify the
protein. Quantitation of proteins in 2D-PAGE has been
largely improved with the development of the differ-
ence gel electrophoresis (DIGE) technique (60). In
DIGE-based proteomics, up to three samples are deri-
vatized using different fluorophores of the cyanine
series and then run on the same gel. This is currently
one of the most reliable routine platforms for quan-
titative proteomics.
Its strengths are low experimental variation due to
mixing of experimental and control samples, and
inclusion of an internal standard, potential visualiza-
tion of protein isoforms including splice variants and
PTMs, and precise information obtained on molecular
weight and pI (60, 61). In addition, the cost for 2D elec-
trophoresis is relatively low, which is an important
issue for healthcare systems. However, the technolo-
gy has distinct limitations. Proteins with either low
(-5000 Da) or high ()1,50,000 Da) molecular weight
and certain physico-chemical properties (e.g., hydro-
phobic membrane proteins) are very difficult to sep-
arate and detect, or may not be detectable at all.
Furthermore, low-abundant proteins in complex sam-
ples such as plasma or cell extracts are not detected
because they are masked by highly abundant proteins
like albumin. This makes it impossible to determine
low- and highly abundant proteins simultaneously.
Sample fractionation, based, for example, on cellular
components, can help overcome this limitation by
reducing the complexity of the sample.
However, any method used to reduce complexity is
bound to introduce artefacts and to increase noise,
influencing the statistical significance of the data pro-
duced. High-throughput protein analysis is hampered
by time consuming separation and tedious staining
and destaining processes. The lack of widely accepted
automation resulting in the requirement for experi-
enced academic and technical staff make it difficult
to introduce 2D-PAGE into the clinical routine. Until
now, almost no parameter for clinical diagnostics is
routinely measured using 2D-PAGE. This method is
restricted to clinical research tasks such as discerning
undefined fluids (skull fracture and suspected CSF
leak), CSF (Creutzfeldt-Jakob disease marker), and
plasma and urine analysis (undetectable paraprotei-
nemia, etc.).
Liquid chromatography (LC) High-resolution LC sep-
aration coupled with MS has recently become a wide-
ly used platform for proteomics. The fractionation of
samples is based on biophysical properties such as
surface charge (ion exchange chromatography),
hydrophobicity (hydrophobic interaction chromato-
graphy) or affinity for certain compounds waffinity,
dye ligand, reversed-phase liquid chromatography
(RPLC)x (49, 56, 62–64). These LC techniques can be
applied to the characterization of complex protein
mixtures utilizing two different strategies. The intact
proteins can be separated and then digested prior to
characterization by MS (‘‘top-down’’ approach), or the
complete mixture can be digested and the peptides
separated and characterized (‘‘bottom-up’’ or ‘‘shot
gun’’ approach). Although the bottom-up strategy
relies on the analysis of protein fragments that are
sufficiently unique to enable identification of the par-
ent protein, this strategy still accounts for the majority
of proteomics approaches. Both strategies have
advantages and disadvantages. While the chromato-
graphic separation of certain proteins, such as those
that are labile or hydrophobic, pose a serious problem
to a top-down approach, some information (e.g., on
splice variants, degradation, assignment of PTMs)
may be lost in a bottom-up approach. Furthermore,
digestion of a protein mixture (e.g., with trypsin)
increases the complexity by at least one order of mag-
nitude. In order to address this problem, multi-dimen-
sional protein identification technologies (MudPIT)
have been developed recently (65, 66). Following
sample reduction, alkylation and digestion, the result-
ing peptide mixture is separated using cation-
exchange chromatography followed by reverse-phase
chromatography and tandem MS. With the recent
development of high-speed 2D linear ion trap instru-
ments such as linear trap quadrupole (LTQ), protein
profiling coverage has been greatly enhanced com-
pared with traditional three-dimensional ion trap sys-
tems (67).
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In conclusion, LC-MS/MS technologies now routine-
ly allow for the identification of thousands of proteins
in complex samples from mammalian tissues and
cells. Although routinely used for peptide/protein
identification, data-dependent LC-MS/MS still has an
inherent limitation of ‘‘undersampling’’, whereby only
a portion of the species observed in the survey MS
scan is selected for fragmentation (66, 68). The LC
unbiased technique allows largely automated high-
throughput analysis. However, quantitative data usu-
ally is not obtained in all laboratories. LC-MS/MS is
already in use for routine clinical analysis, especially
for inborn errors of metabolism. However, instru-
ments dedicated to routine clinical use are still
desired, and this has the potential to become a widely
used method (see Applications).
Capillary electrophoresis (CE) CE, especially capil-
lary zone electrophoresis (CZE), is frequently used as
a front-end coupled to a mass spectrometer. The
separation of proteins in CE is based primarily on
their charge to mass ratios, size-sieving effects-, inter-
action with ligands (affinity) and/or hydrophobicity/
hydrophility (partition). CE coupled to MS offers
several advantages: 1) it provides fast separation and
high-resolution (69), 2) it is robust and uses inexpen-
sive capillaries instead of expensive LC columns (70),
3) it is compatible with most buffers and analytes (71),
and 4) it provides a stable constant flow, thereby
avoiding gradients in the buffer that may otherwise
hamper MS detection (72). However, CE cannot be
easily applied for high-molecular weight proteins,
which can be removed effectively by techniques such
as ultrafiltration (73). Another limitation of CE-MS is
the relatively small sample volume that can be loaded
onto the capillary, resulting potentially in lower sen-
sitivity for detection, or loss of discrimination. Despite
technical improvements, the complexities of human
body fluids and the problem of high-dynamic range
provides significant challenges for using CE for
routine proteomic profiling.
In conclusion, although CE and CZE offer high-
throughput and automation capabilities, along with
sensitivity and good resolution power, the combina-
tion of these separation techniques with MS for
routine proteomics has just recently become com-
mercially available. This is due primarily to poor
reproducibility, complicated configurations and the
need of skilled operators (74).
Mass spectrometry (MS) MS technologies provide
the backbone for the majority of proteomic research.
The rise of proteomics can be attributed to the avail-
ability of completely sequenced genomes since 1995,
together with advances in protein ionization, in-
creased resolution, improved sensitivity and high-
throughput MS analyzers available since the late
1980s, along with the development of protein com-
putational search algorithms.
A mass spectrometer consists of an ion source to
introduce the analytes to gas for ionization, one or
more mass analyzers for measurement of the m/z
ratio of the ionized analytes and a detector for the
determination of the number of ions at every m/z
ratio.
Of the ionization techniques available today, elec-
trospray ionization (ESI), which forms the ions from a
liquid solution, and matrix-assisted laser desorption/
ionization (MALDI) using a laser pulse to sublimate
the analyte from a dry matrix, provide high-sensitivity
and can generate ions without significant chemical
decomposition such as the breaking of covalent
bonds (75–78). Using electrical voltage, ions are
accelerated into the mass analyzer and the m/z values
are measured by the motion of the ions through the
mass analyzer. An example of a mass analyzer fre-
quently used is the TOF analyzer that separates ions
based on the differences in transit time (time of flight)
from the ion source to the detector through tubes
under vacuum. By placing two analyzers in sequence,
two-stage MS can be performed (tandem MS or MS/
MS). Peptide sequences are identified by comparing
experimental mass spectra with theoretical mass
spectra using protein databases and search algo-
rithms such as SEQUEST, MASCOT, PHENYX and !X-
TANDEM (79–83). The amino acid sequence of the
whole protein can be determined by matching the
mass spectrum to known spectra using search algo-
rithms such as SEQUEST (81), MASCOT (80) or PHE-
NYX (82).
One analytical problem is that ionization is never
100% efficient due to the physico-chemical properties
of the analyte molecules, including pKa value, polar-
ity, hydrophobic or hydrophilic index, and ionization
potential. In addition to the variability in ionization
potential between various peptides, the efficiency of
ionization is directly influenced by the concentration
and type of peptides infused into the atmospheric
pressure ionization (API) source. The higher the pep-
tide concentration, the lower the capacity to suffi-
ciently ionise all available peptides due to depletion
of all available protons and to upper mass density
constraints in the dynamic range of the mass spectro-
meter.
The majority of MS protein identification is based
either on the characterization of short, unique (; 6–10
amino acid) peptide sequences (tags), or on spectra
comparison. With the automation and software that
is available, more than 1000 spots or bands can be
prepared and measured by a single person per day
using MALDI-TOF-TOF MS. A limitation of MALDI-TOF
is the identification or detection of low molecular
mass proteins which deliver so few peptides that
identification is often based using a low number of
matches. The MALDI-TOF-based protein identification
approach cannot identify multiple components of a
mixture. In most cases, e.g., in protein spots from 2D
gels, the major component of a protein mixture is
identified using MALDI-TOF from one single spot.
Highly homologous proteins are sometimes difficult
to distinguish with current software (84). Another
problem is that it is not possible to directly identify
potential biomarkers. Signals such as acute-phase
responses or artefacts cannot be filtered out and may
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be identified as biomarkers. To handle this limitation,
tandem MS techniques and/or cumbersome purifica-
tion is required.
Despite this limitations, MALDI-TOF-MS and ESI-
MS/MS, combined with LC, are widely used for clini-
cal proteomics and have contributed significantly to
the human proteome organization-Plasma Proteome
Project (HUPO-PPP) which has aims of creating a
comprehensive database of all plasma and serum
constituents and characterising the sources of varia-
tion within individuals over time. The collaborative
effort of the HUPO initiative has analyzed standard-
ized human plasma samples using various proteomic
platforms. Through this effort, 3020 proteins have
been qualitatively identified, each identification based
on a minimum of two high-scoring MS/MS spectra. A
critical step subsequent to protein identification is
functional annotation. A subset of proteins from this
project was annotated for relevance to cardiovascular
disease. Most of the proteins in the vascular and
coagulation system and markers of inflammation
have been shown to localize in plasma, whereas the
majority of other groups such as signaling, growth
and differentiation, cytoskeleton, transcription factors
or channels and receptors hosted a larger number of
novel plasma components. Knowledge of the role of
these plasma constituents on the cardiovascular sys-
tem can provide insights into their roles in the plasma
(85). The study of Donahue et al. lead to the discovery
of proteins related to coronary artery disease using
large-scale proteomic analysis of pooled plasma.
They analyzed 53 males with angiographic coronary
artery disease and 53 control subjects without coro-
nary disease from the Duke Databank for Cardiovas-
cular Disease. Major plasma protein abnormalities
were excluded. Plasma samples from each group
were pooled to identify low-abundance proteins. After
removal of albumin and immunoglobulins, and
enrichment of smaller proteins (-20–40 kDa), sam-
ples were separated into 12,960 fractions by one cat-
ion exchange and two reversed-phase chroma-
tography steps. Proteins were analyzed using LC-ESI-
MS-MS. They could identify 731 plasma proteins or
fragments thereof. Of these proteins, 95 were differ-
ent between cases and controls. These represent
broad categories of proteins involved with natural
defence, inflammation, growth, and coagulation (86).
Surface enhanced laser desorption/ionization
(SELDI) SELDI-TOF-MS, first described by Hutchens
and Yip, is a hybrid technology combining chip-based
solid phase chromatography with TOF-MS. In brief,
incubating samples with chips whose surfaces are
coated with a protein-fractionating resin allows cer-
tain proteins to become attached to the chips (87).
After washing the unbound components away, an
energy absorbing matrix is layered over the chips.
Spectra are acquired using laser ionization and TOF
separation MS. This allows protein separation and
MS analysis to be performed using the same analysis
system. Also, due to the chip format, high-throughput
of up to 80 samples/day using current systems, low
sample volume (1 mL; 25–50 cells, peptides in the
fmol range) and relatively short analysis time can be
achieved. Chips contain a chromatographic surface
that can enrich protein subsets according to predefi-
ned conditions on a given surface; combining differ-
ent surfaces and conditions facilitates the compre-
hensive analysis of complex protein mixtures.
A great number of studies have been published in
recent years with currently close to 600 Medline
entries for SELDI. Many of these studies have been
directed towards the search for new biomarkers.
However, studies on protein-protein and protein-DNA
interactions, transcription factors and protein phos-
phorylation have also been performed. The possibility
of binding specific antibodies to the chip also resulted
in reports of the identification of isoforms and modi-
fications of proteins such as troponin I and transthy-
retin. The commercial availability of this system and
the advantages mentioned above regarding fast sam-
ple analysis are the main reasons why such a great
number of studies attempting to translate proteome
analysis in human specimens to clinical diagnostics
have been performed using the SELDI platform. Con-
sequently, many of the general problems of the
proteomic approach regarding pre-analytical and ana-
lytical issues, as well as data interpretation and vali-
dation of results have been raised and discussed in
great detail with respect to SELDI. Also, there are a
number of methodological criticisms specific to the
SELDI platform that deserve close attention and must
be considered when comparing and evaluate systems
designed for clinical applications of proteome analy-
sis. These methodological criticisms, along with the
basic principles and limitations of the method, have
been reviewed extensively by Poon (88). The quality
of the mass spectrometer component of available sys-
tems is under debate, especially its effect on resolu-
tion and sensitivity. Another point is the fact that
proteins cannot be identified directly in the SELDI
platform, instead requiring mass patterns for diag-
nosis. There is consensus, and it has been shown in
a number of studies, that utmost efforts must be
made to standardize and wherever possible automate
the entire analysis to obtain acceptable precision and
reproducibility. Bearing these limitations in mind, and
considering the general precautions set out in this
document, it should be noted that at present the
majority of studies describing the application of pro-
tein marker patterns in clinical studies have been
obtained with this technique. Advances in developing
other more robust and precise methods that can be
used for high-throughput analysis of small samples
may change this situation.
Array-based proteomics High-density DNA microar-
ray technology has played a key role in the analysis
of the whole genome and gene expression patterns.
Protein arrays are emerging to follow DNA microar-
rays as a potential screening tool for identifying pro-
tein-ligand interactions, and have great potential as a
research and diagnostic tool for parallel processing of
complex samples.
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For array-based proteomics, molecular probes
designed to capture specific proteins at specific sites
are deposited on a solid support. To date, a large rep-
ertoire of solid supports based on glass-, plastic-,
PVDF- or silicon-slides, often with chemically modi-
fied surfaces, are available. Molecular probes can be
monoclonal or polyclonal antibodies, robust affinity
proteins based on the structure of protein A (antibod-
ies), highly thermostable members of large combi-
natorial libraries, mimicking natural ankyrin repeat
proteins in E. coli cultures (ankyrin repeat proteins) or
short lengths of single-stranded DNA or RNA mole-
cules (aptamers). Arrays are probed with cell culture
supernatants, cell lysates or serum. Depending on the
molecular probes used, proteins or antibodies in the
sample are bound by the planar array. The bound
molecules are detected by a secondary antibody
marked with a fluorescent dye, or directly if the sam-
ple has been fluorescently labeled. The incubated
chips can be read by a variety of scanners based on
non-confocal, confocal and planar wave guide tech-
nology (89).
The determination of autoantibody profiles with
protein biochips promises to be a valuable part of
future clinical diagnostics. Autoantibodies have
already proven their usefulness in routine clinical
diagnosis as surrogate and non-surrogate biomar-
kers. Some have been shown to be useful for disease
monitoring and can be detected years before the
onset of a disease (90). The systematic identification
of potential disease-specific antigens opens the pos-
sibility for new diagnostic and therapeutic tools and,
therefore, potential for economic gain. Screening sera
or plasma from patients with protein arrays would not
only allow the identification of potentially new anti-
gens, but also enable the diagnosis and subtyping of
autoimmune diseases based on the presence of spe-
cific auto-antibodies. This had lead to the profiling of
the antibody repertoire of patients with various dis-
eases. In a series of pioneering studies a number of
putative novel autoantigens have been identified from
one of the largest collections of recombinant human
protein expression clones (Uniclone technology,
www.protagen.de) using pools of patient sera
(91–93). The UNIclone collection consists of ;
11,000 different, sequence-characterized human
recombinant proteins. In a different approach, a pro-
tein array consisting of 196 structurally diverse bio-
molecules representing major autoantigens was
probed using serum from patients with various auto-
immune diseases including systemic lupus erythe-
matosus, Sjo¨gren syndrome and rheumatoid arthritis.
There were distinct autoantibody patterns for the dif-
ferent autoimmune diseases suggesting their utility
for diagnosis (94). A new technique, termed layered
peptide array, can serve as a screening tool to detect
antibodies in a highly multiplexed format. The pro-
totype was capable of producing ; 5000 measure-
ments/experiment. For Sjo¨gren syndrome, this
platform exhibited both a high-sensitivity (100%) and
high-specificity (94%) for correctly identifying Sjo¨gren
syndrome antigen B antigen-positive samples from
patients with Sjo¨gren syndrome (94, 95). Apart from
tumor marker or autoantibody identification, cytokine
networks in inflammation or transplant rejection may
be detected by planar or bead-based protein arrays.
Following the development of disease-specific or
disease group specific planar protein arrays, clinical
laboratories can easily adopt such protein biochips
because they are compatible with established and
affordable DNA microarray scanners. Furthermore,
new biochip platforms allow handling of multiple
samples in a microtiter plate like format.
In addition to diagnostics, planar arrays can also be
applied for the development of therapeutic antibod-
ies. In this context, a protein biochip tool has been
developed to speed up antibody research and to
reduce the risk of failure based on its UNIclone col-
lection. These commercially available biochips (UNI-
chip AV-400 and UNIchip AV-VAR, www.protagen.
de) are used to determine sensitivity, epitope speci-
ficity and the level of cross-reactivity of these anti-
bodies. An added value is ‘‘faster selection of the
best’’ antibodies prior to expensive animal experi-
ments or clinical trials. Protein microarrays belonging
to the UNIchip series will be applied to further inter-
action studies such as screening for protein kinase
substrates, protein-protein interaction as well as pro-
tein-small molecule interaction.
Bead-based immunoassays for protein analysis
Apart from planar microarrays, bead-based systems
provide an alternative when the number of parame-
ters to be determined in parallel is rather low. In bead-
based assay systems, latex microspheres are used as
the solid phase and allow rapid binding kinetics and
facilitate the separation step (1). Microsphere based
assays have become an attractive alternative to the
popular microtiter plate based, enzyme linked immu-
nosorbent assay (ELISA). Sensitivity, reliability, and
accuracy of microsphere based arrays are similar to
those observed with well-established ELISA proce-
dures. In fact, since 10,000 beads or more are meas-
ured for each analyte, and since each bead can be
regarded as a single immunoassay, the precision of
the test results is usually very favorable. Bead-based
assay systems also have several advantages over pla-
nar microarrays (96). Probe molecules can be conju-
gated with millions of microspheres with high
reproducibility. The composition of the panel of test
parameters can be defined by the user by simply add-
ing or removing beads with different probes; with a
planar array the probe molecules are fixed. In addi-
tion, binding of the molecules in patient samples can
be accelerated by mixing the probes, which is not
always possible using planar protein arrays.
In contrast to planar arrays, probe molecules can-
not be coded by their position on the protein chip. In
steady, they have to be coded by variations in the
microspheres they are attached. One example would
be by variations in color or size. Most of the available
assay systems use color coded microspheres. The
beads are filled with one or more fluorescent dyes
and can be measured with a flow cytometer. The
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amount of captured target protein is quantified using
a reporter system. Although this methodology is well-
suited for single-analyte analysis, it is more desirable
to rapidly and simultaneously quantify multiple ana-
lytes using a relatively small sample size. Sample size
becomes a critical factor in the evaluation of multiple
analytes. This technique enables multiplexed immu-
noassays with the use of multiple microspheres that
can be discerned by different fluorescent labels as
solid supports that are coated with specific antigens
or antibodies. A set of a hundred different color coded
beads is commercially available for multiplexed
ligand-binding assays (www.luminexcorp.com, www.
bdfacs.com, www.illumina.com). For example, Lumi-
nex Corp offers microspheres coded by two dyes at
ten different concentrations. Thus, up to 100 different
sets with each matched to a different probe molecule
can be used (97, 98). Such systems have been used
to determine the concentration of cytokines (97, 99),
screening for cystic fibrosis (97, 100), hepatitis B sero
conversion and human immunodeficiency virus (97,
101, 102), thyroid hormones (97, 103), kinase testing
(97, 104), allergy testing (97, 105), single nucleotide
polymorphisms (97, 106), infectious disease diagnosis
(97, 107), and detection of biological warfare agents
(97, 108) or antibodies in serum or cell culture super-
natant (109, 110).
Another possibility for distinguishing different
beads is to generate microspheres of different sizes.
These can be differentiated by light scatter. Combin-
ing both forms of beads, one could scale up to many
more parameters in one test (97). Multiplexed analy-
sis of protein-protein interactions (111), or the simul-
taneous characterization of the binding of auto-
antibodies to multiple epitopes (112) are promising
applications of flow cytometric bead-based assays.
In conclusion, bead-based immunoassays are wide-
ly used in the routine laboratory setting for the detec-
tion of cytokines or autoantibodies in serum (109).
Due to the high-specificity and high-sensitivity, bead-
based microarrays are currently a primary assay
platform in clinical proteomics. They are easy to
handle and the analyzers are affordable for most
laboratories.
Applications of proteomics and peptidomics
of body fluids for the clinical laboratory
Preparation of clinical samples for fluidic proteomics
Considering the multiple challenges arising from the
complexity of disease processes, the heterogeneity
and variability of human clinical samples, and the
very low concentration of potential biomarkers in
plasma, it is still questionable whether a direct pro-
teomics approach, such as MS/MS, will reliably detect
disease biomarkers in unfractionated plasma or
serum in a routine clinical setting. Therefore, it is nec-
essary to distinguish clinical proteomic applications
from clinical proteome studies in medical research
directed at understanding rather than diagnosing dis-
ease. This distinction is pivotal in any discussion on
sample sources, sampling, sample quality, and the
entire pre-analytical and analytical process in proteo-
mic studies.
With a clear understanding of the task at hand, it is
mandatory to establish SOPs adapted to the specific
requirements prior to collecting samples. SOPs must
cover the entire process comprising collection, han-
dling, preparation and storage, analysis of samples,
including isolated cells and plasma, liquor, bronchoal-
veolar lavage (BAL) and urine (113, 114). It has been
proposed that collection of urine is less challenging
as there is little proteolytic degradation for several
hours and, therefore, no additives are required (115).
However, this has yet to be substantiated. Using a
standardized protocol employing magnetic bead sep-
aration and MALDI-TOF-MS, Fiedler et al. detected
427 different mass signals in the urine of healthy
donors and found acceptable within- and between-
day imprecision (116). However, they worked with
highly abundant proteins and this statement may not
be true for less abundant or rare proteins. Well
designed biomaterial repositories using on carefully
planned collection and storage of clinical samples
that are annotated with high-quality, disease-related
clinical data (case history, diagnostic phenotype,
treatment scheme, etc.), and maintained in a stan-
dardized format that can be used to compare results
across studies will be a prerequisite for biomarker val-
idation. It must be emphasized that problems with
preanalytical standardization are prone to arise in the
time period between collection of the biomaterial and
its arrival at the laboratory. Quality management con-
cepts such as the international accreditation norm EN/
ISO 15,189 for medical laboratories proposes to place
the preanalytical phase under the responsibility of the
clinical laboratory. With compliance from clinical
units, such regulations may improve the preanalytical
phase. In their recent reviews, Luque-Garcia (4) and
Paik (3) elaborate on the issues of clinical proteomics
with emphasis on fluid proteomics and the prepara-
tion of clinical specimens and technological aspects
of proteomic profiling.
Plasma/serum In laboratory diagnostics, human
blood is the most frequently analyzed sample as
serum, plasma or separated blood cells. Since blood
is in contact with every organ and, therefore, contains
proteome subsets of other tissues, it is the most com-
plex human derived proteome. The number of serum
proteins is estimated to be 10,000.
In principle, proteomics shows great promise for
the study of proteins in plasma and a number of pro-
teomic databases have already been established. A
challenging problem of plasma proteome analysis is
the dynamic range of protein concentrations which
can be as much as 10 orders of magnitude. For exam-
ple, albumin is present in blood at millimolar (10–3)
concentration while many cytokines, such as tumor
necrosis factor (TNF), are physiologically active at
concentrations between 10–12 mol to 10–9 mol (117).
Furthermore, only 10 proteins constitute 95% of the
entire mass of plasma proteins (118). Since biomarker
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discovery means searching for low-abundance pro-
teins, the efficiency of fractionation systems are
essential to avoid interference from abundant pro-
teins. Therefore, development of multi-dimensional
fractionation methods is vital to overcome the effects
of ion quenching which is responsible for insufficient
diagnostic sensitivity in unfractionated material. Two
major depletion methods are used; resin based and
antibody based depletion (e.g., multiple affinity
removal system MARS). Several different techniques
for plasma protein fractionation have been employed
including 2D liquid enrichment system (Gradiflow),
plasma fractionation using multichannel electrolyte
(MCE) and microscale solution isoelectric focusing
(IEF) ZOOM, and free flow electrophoresis (FFE) (119,
120). However, caution is needed so that removal or
pre-fractionation steps will not disturb the quantita-
tive composition of the original sample and may mis-
leading results.
In conclusion, obtaining proteomic profiles of
uncharacterized and unidentified molecules is certain-
ly advantageous in comparison with standard immu-
noassay measurements since a protein fingerprint
can be obtained rapidly from as little as 1 mL of
unfractionated patient serum. This small sample can
be analyzed using MS approaches to rapidly generate
a unique proteomic signature of the serum (121). A
general limitation of this approach is that MS-based
methods select for the most abundant peptide ions
and peaks making it likely that markers present in
minute amounts are left undetected. Current immu-
noassays are able to detect low abundant proteins at
a sensitivity of up to 10–14 or even 10–17.
Urine The composition of urine is highly variable.
The variability of its composition is a major way in
which the ‘‘milieu interieur’’ is kept more or less con-
stant in the face of environmental and nutritional
changes. General problems with urine in laboratory
diagnostics also apply to clinical proteomics. These
problems consist of: 1) difficulties in standardizing
sample collection and handling, 2) volume changes
related to concentration changes and salt composi-
tion which vary widely, and 3) frequent contamina-
tion, especially in 24 h urine. In disease, there is
frequently proteinuria and bacteriuria even in appar-
ently healthy individuals. On the other hand, urine
protein diagnostics has used pattern approaches and
qualitative analyses for a long time.
The filtered plasma ‘‘peptidome’’ is normally proc-
essed by the proximal renal tubule. The proximal
tubule removes substantial but undefined amounts of
peptides and proteins from the filtrate. In addition,
proteins are shed from the urinary track wall and from
the bladder epithelium. Numerous cellular and
membrane proteins are found in normal urine. When
the proximal tubular reabsorption process is ineffec-
tive, as in the renal Fanconi syndrome, large quanti-
ties of plasma peptides are found in urine. In order to
use urine as a source of reliable peptide biomarkers
in disease, one has to define how variables within
urine itself (‘‘endogenous variables’’), such as salt
composition and pH, influence peptide recoveries. In
addition, sample processing variables (‘‘exogenous
variables’’), such as freeze-thaw cycles, affect results.
A single freeze-thaw cycle can produce dramatic
changes in the intensity of several urinary peptides.
The ‘‘urinary peptidome’’ promises to be a resource
at least as dynamic and informative as the ‘‘urinary
proteome’’. However, urine, as a matrix, is one of the
least desirable biological fluids for both peptidomic
and proteomic work. There are three main problems:
(a) as is the case for proteins, the range of peptide
concentrations in urine spans several orders of mag-
nitude, (b) we still cannot quantify most of the pep-
tides, and (c) beyond their mass measurement, we do
not know their structure. A significant difficulty is the
presence of large quantities of uromodulin (‘‘Tamm-
Horsfall protein’’) in urine. Uromodulin is the single
major protein in healthy urine. The problem is that
uromodulin forms fibrils which in turn form sediment
depending on salts and pH. This is important because
uromodulin is known to bind several LMW proteins
and plasma peptides that enter the tubular filtrate.
The elucidation of disease-specific biomarkers in
urine is complicated by significant changes in the
urinary proteome during the day. These changes are
likely due to exercise, variations in diet and circadian
rhythms (122). Thus, the reproducibility of biological
assays is reduced because of physiological changes,
and not due to poor reproducibility of the analytical
method. In addition, differences between first void
and midstream samples have been noted (Mischak et
al., personal communication), highlighting the impor-
tance of standardized protocols for the collection.
Certainly, we do not always have the choice how to
collect urine. When considering urine collection in
babies non-invasive sampling is preferred compared
to biopsy. Apparently CE-MS, due to the detection of
large numbers of peptides, is less sensitive to these
variations than other methods. This variability in pro-
tein profiles highlights the difficulties in establishing
a ‘‘normal human urine proteome map’’. Using urine
samples from healthy volunteers following acetone
precipitation, Thongboonkerd et al. (123) defined the
first human proteome map, consisting of 67 proteins
and their isoforms that could be used as a reference.
In a subsequent study by Oh et al. (124), pooled urine
samples from 20 healthy volunteers were used to
annotate 113 proteins using 2-DE peptide mass fin-
gerprinting (PMF). Additional experiments that further
expanded the knowledge of the normal urinary pro-
teome have been reported and ; 800 proteins have
been identified in the urine proteome (125, 126).
Mann and co-workers identified more than 1543 pro-
teins in normal urine pooled from ten people using
gel and LC Fourier transform (FT)-MS/MS and Orbi-
trap MS/MS (127).
A direct comparison of identical urine samples
using SELDI with CE-MS by Neuhoff et al. (128) result-
ed in the identification of three potential biomarkers
using SELDI, and 200 potential biomarkers using CE-
MS analysis. The authors concluded that it is neces-
sary to characterize any disease by using a panel of
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well-defined biomarker proteins rather than a few ill-
defined peaks. Mischak and co-workers (129–131)
used CE coupled to MS, together with appropriate
software solutions, to analyze urine and other body
fluids to diagnose various kidney disorders based on
well-defined protein patterns. With this approach
each protein is defined by its mass and migration
time, and the signal intensity serves as measure of its
abundance (70, 132). The urine samples were ana-
lyzed individually and the data from the individual
CE-MS runs were combined due to the high repro-
ducibility of the method. This feature allows compi-
lation of datasets and comparison of the different
groups; for example patients with a specific kidney
disease compared to patients with other types of kid-
ney disease or healthy controls. This comparison
allows evaluation of an array of biomarkers that dif-
ferentiate healthy subjects from patients, as well as
other markers that define the specific disease or clin-
ical condition. The latter type of biomarkers is useful
for differential diagnosis. CE-MS permits fast and
reproducible analysis and differentiation of protein
patterns based on dozens of protein markers. Panels
of 20–50 protein markers enabled diagnosis of a spe-
cific (primary) kidney disease as well as discrimina-
tion between different kidney diseases with high-
sensitivity and specificity such as IgA nephropathy,
focal-segmental glomerulosclerosis, membranous
glomerulonephritis, minimal change disease, and dia-
betic nephropathy (133, 134). In this context, urine
proteome diagnostics may represent a diagnostic
approach to kidney disease without significant mor-
bidity when compared with invasive kidney biopsy. In
a recent study Decramer et al. (135) used CE-MS
based urinary proteome analysis to define specific
biomarker patterns for different grades of ureteropel-
vic junction obstruction, a frequently encountered
pathology in newborns. Of note, these patients did
not have any sign of increased proteinuria. In a blind-
ed prospective study, these patterns predicted, with
95% accuracy, the clinical outcome of these newborns
9 months in advance. This data clearly indicate the
potential of urinary proteomics for diagnosis as well
as prognosis of renal disease. Proteome analysis of
urine has also revealed biomarkers for several non-
renal diseases. As in the case of ureteropelvic junc-
tion obstruction, these diseases generally do not
result in increased proteinuria. Not surprisingly, bio-
markers for urothelial cancer have been detected in
urine. While the first studies using SELDI technology
analyzed few samples and reported different biomar-
kers for the same disease (136, 137), Theodorescu et
al. (115) recently used CE-MS to assay more than
600 samples, including 180 samples examined in
blinded fashion as a validation set. The biomarkers
found by these investigators correctly classified all
blinded urothelial cancer samples and normal con-
trols. However, nine of 138 patients with various
chronic kidney diseases or nephrolithiasis were incor-
rectly classified as having urothelial cancer. Kaiser et
al. (138) found biomarkers for graft-versus-host dis-
ease (GvHD) following bone marrow transplantation
using CE-MS-based urine proteomics. GvHD leads to
endothelial dysfunction, which may also alter kidney
structure and/or function. This complication can affect
filtration and urine production resulting in disease-
specific proteins being excreted in the urine.
Other body fluids Body fluids such as CSF, bron-
choalveolar lavage (BAL), lacrymal, salivary, pleural,
pericardic, pancreatic and synovial fluid, ascitis, bile
and semen also are interesting clinical samples for
proteomic analysis. CSF samples are collected by
lumbal puncture. CSF has to be centrifuged to remove
cells (e.g., at 250=g for 10 min) and the supernatant
has to be stored at least at –808C with or without the
addition of protease inhibitors. Because of the low
protein concentration in CSF, sample preparation usu-
ally includes protein enrichment techniques such as
ultrafiltration. Columns with different molecular
weight cut-offs can be used alone or in combination.
For example, Centricon YM-50 columns (Millipore,
Bedford, CA) with a nominal molecular weight cut-off
of 50 kDa may be used with Ultrafree columns (Mil-
lipore) with a molecular weight cut-off of 5 kDa.
Potential serum biomarkers for early stroke have been
identified using SELDI-TOF analysis. Analysis of CSF
by MS has led to the identification of potential bio-
markers for Alzheimer’s disease (139) and potential
biomarkers for stroke have been confirmed in serum
of a large cohort of patients (140).
Problems with BAL samples include inconsistent
dilution of the proteins in lung, depending on the frac-
tion recovered. In addition, reference values from
healthy donors are difficult to establish as BAL is indi-
cated for patients with lung diseases only, and BAL is
rarely performed on healthy probands. Over the
years, the European Respiratory Society (ERS) task
force has drafted documents on methods for perform-
ing BAL (141). BAL sample preparation and process-
ing needs to be standardized and should follow
international guidelines to make the results reproduc-
ible and comparable wInternational Scientific Societies
of Respiratory Diseases (ATS/ERS) (142)x. BAL is usu-
ally performed during bronchoscopy for a variety of
indications such as diagnosis and follow-up (143). Ali-
quots (50–60 mL) of phosphate buffered saline (usu-
ally four or five) are instilled by a fiber optic
bronchoscope and the fluid is recovered by gentle
aspiration. Recovery varies with lung site or type of
disease. The first sample is generally kept separate
from the others because it contains more debris and
bronchial contamination and is not used for proteome
analysis. The other aliquots are filtered and centri-
fuged to separate cells from the fluid component. The
supernatant can be frozen at –808C until analysis. Cell
differential counts are performed using cytocentrifuge
preparations. The phenotype of lymphocytes and
macrophages, or other cells, can be analyzed by flow
cytometry using mAb (144). The study of BAL by use
of sophisticated techniques such as proteomics
requires better standardization of the method to
reduce variability. For example, for 2-DE analysis,
BAL samples must be desalted and concentrated to
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obtain a suitable protein content. Factors linked to
sample variability need to be considered. These fac-
tors include the quantity of fluid instilled, the minimal
accepted percentage recovery, the type of aspiration,
and the choice of site in the lung. Reference para-
meters are chosen to express the results, for example
as mg of total protein, or albumin.
Diagnostic analysis of saliva for oral as well as sys-
temic diseases depends on the identification of bio-
molecules that reflect characteristic changes in their
presence or absence and the composition or structure
of saliva components found in healthy and disease
conditions. Most of the biomarkers suitable as diag-
nostic aids comprise proteins and peptides. The use-
fulness of salivary proteins for diagnosis requires
recognition of typical features, making saliva unique
among body fluids. Salivary secretions reflect a
degree of redundancy displayed by extensive poly-
morphisms for families among each of the major sal-
ivary proteins. The structural differences among these
polymorphic isoforms range from distinct to subtle,
which may in some cases not even affect the mass of
different family members. Knowledge of the structure
and function of salivary derived proteins/peptides has
a critical impact on the timely and correct identifica-
tion of biomarkers, whether they originate from exo-
crine or non-exocrine sources (145).
Histological and functional changes of the lacrimal
gland might be reflected in proteomic patterns in tear
fluids. For example, determination of disease biomar-
kers in tear fluid for Sjo¨gren’s syndrome could lead
to a non-invasive diagnostic test based on proteomic
patterns. In a study with 31 Sjo¨gren syndrome
patients and 57 control subjects, protein profiling in
tear fluids was identified using SELDI-TOF-MS. Mul-
tiple protein changes were detected reproducibly in
the primary Sjo¨gren syndrome group, including 10
potential novel biomarkers. Seven of the biomarkers
(m/z 2094, 2743, 14,191, 14,702, 16,429, 17,453,
17,792) were down-regulated and three biomarkers
(m/z 3483, 4972, 10,860) were up-regulated in the pri-
mary Sjo¨gren syndrome group, comparing to the pro-
tein profiles of control subjects. When the cut-off
value of the Sjo¨gren syndrome score was set -0.5,
87% sensitivity and 100% specificity was achieved.
The positive predictive value for this sample set was
100%. These findings support the potential of proteo-
mic pattern technology in tear fluids for primary Sjo¨-
gren syndrome (146). However, one disadvantage is
that this technique is unable to identify specific
proteins.
Proteomic analysis of PTMs
Recent information on PTMs makes it possible to
interpret biological regulation with new insights. Var-
ious protein modifications fine tune the cellular func-
tions of each protein. Understanding the relationship
between PTMs and functional changes is another
enormous task, not unlike the human genome project.
Proteomics, combined with separation technology
and MS, makes it possible to dissect and characterize
the individual parts of PTMs, and provide a systemic
analysis. Systemic analysis of PTMs of various sig-
naling pathways has been applied to illustrate the
kinetics of modifications. A variety of chemical mod-
ifications have been observed in proteins and these
modifications alone, or in various combinations,
occur in a time and signal dependent manner. PTMs
of proteins determine their tertiary and quarternary
structures and regulate their activities and functions.
Recent advances in proteomic methodology, includ-
ing MS, make it possible to identify proteins in com-
plexes very rapidly (147). While protein identification
can be accomplished using sequencing or mapping
only a few peptides, mapping of PTMs requires the
complete coverage of peptides comprising a protein.
Protein modifications probably do occur in-vivo in
more than 90% of proteins. Furthermore, the samples
are a heterogeneous mixture of modified and unmo-
dified proteins that are present in different propor-
tions. Current proteomic technology is useful for
detecting only simple modifications in large amounts
of modified samples, not for thorough mapping of all
endogenous protein modifications. Since proteomic
methodology has tremendous potential for under-
standing PTMs, many efforts are being advanced for
enriching modified samples and specific detection of
modifications. Major types of PTMs are phosphory-
lation, acetylation, glycosylation, methylation, farne-
sylation, lipidation, GPI-anchors, sumoylation and
ubiquitination (148, 149).
Bioinformatic approaches in fluid proteomics
Although there are examples where a single labora-
tory parameter allows good clinical support for the
diagnosis of disease, for example, troponin in myo-
cardial infraction, most proteomic studies indicated
that a single biomarker may be not adequate for reli-
able diagnosis, staging or prognosis of disease. The
question arises of how to combine multiple biomar-
kers to provide a diagnostic or predictive pattern.
Although a definitive answer is probably still far in the
future, a number of approaches have emerged.
Among the first algorithms to utilize the available
information on multiple biomarkers were hierarchical
decision tree classification methods, such as Classi-
fication And Regression Trees (CART) (150). Heuristic
clustering is another approach (151, 152). Empirical
observations showed that these approaches are not
successful because incorrect predictions made by the
classification algorithm increased with the complexity
of the decision tree. In addition, the number of data-
sets used for training the decision tree was low,
resulting in a lack of statistical significance beyond
the second or third nodes of the tree.
Support vector machines (SVMs), see reference
(153) for example, seem to be a promising way to
overcome some of these limitations due to the theo-
retical principles upon which they are based. In a
number of diverse applications, excellent empirical
performance of SVMs has been reported. Although
mixed results were obtained with blinded datasets,
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these approaches provide superior cross validated
predictive performance. When the number of
variables was -20, and substantial differences
between the datasets existed, reliable results have
been obtained. However, in cases where subtle dif-
ferences exist, the number of support vectors need to
be increased. This results in over fitting of the clas-
sifiers, to the training set and thus in poor classifica-
tion of blinded datasets (Mischak et al., unpublished
data). This term is also referred to as ‘‘memorizing’’,
a term often employed in artificial intelligence
research. The number of variables and dimensions
have to be decreased in order to avoid memorizing
effects.
An important facet of the use of biomarker combi-
nations for making predictive diagnosis with a clas-
sification algorithm is to have a properly calibrated
indication of the level of confidence in the predictions
being made. A classification such as, ‘‘this serum
sample has been drawn from an individual with type
II diabetes’’, should also have a numeric score denot-
ing how likely or probable it is that the classification
is correct, i.e., ‘‘with 90% confidence this serum sam-
ple has been drawn from an individual with type II
diabetes’’. Of course, 90% confidence is more reliable
than a prediction with 50% confidence, particularly if
there are only two alternatives to be considered. In
the case of presence of disease vs. absence, 50% con-
fidence indicates little more than random guessing.
Such confidence levels, also referred to as probabili-
ties, attached to a classification enable costs of miss-
classification to be assigned in an optimal manner.
Incorrectly predicting the absence of a disease has
more serious consequences than to incorrectly pre-
dicting its presence. SVMs provide encouraging clas-
sification performance for a range of difficult
problems. However, they are devoid of any probabi-
listic semantics and, therefore are unable to provide
levels of confidence attached to any classification.
Thus, the clinician is left with no information as to
how much the predictions should be trusted.
A general purpose and computationally efficient
Gaussian process based classification method has
recently been developed (154). This method has been
successfully applied to the problem of correct predic-
tion of BRCA1 and BRCA2 heterozygous genotypes
(155). This method provides a means of inferring opti-
mally weighted combinations and possible selection
of biomarkers.
Independent of which of these approaches is util-
ized, two basic considerations apply: 1) the number
of independent variables has to be kept to a minimum
and should be below the number of samples investi-
gated, and 2) such an approach is only valid if applied
to a blinded validation set, and it should be manda-
tory to include a blinded dataset in any report on
potential biomarkers.
In a recent report, Rho et al. (156) presented a sys-
tems biology framework, called the ‘‘integrative
proteomics data analysis pipeline’’ (IPDAP), which
generates mechanistic hypotheses from network
models reconstructed by integrating diverse types of
proteomic data generated by MS-based proteomic
analyses. This framework includes a series of com-
putational and network analysis tools and helps to
translate data to biological knowledge.
Data analysis strategies
In pre-clinical research, MS-based proteomics have
become an important component. It is obvious that
the analysis of complex protein or peptide mixtures,
derived from body tissues or body fluids requires
sophisticated data acquisition, handling and process-
ing. Proteomic data needs to be combined and
merged with patient or clinical data and compiled and
integrated with very complex datasets. Highly heter-
ogeneous data architectures are generated that need
to be managed adequately. Data handling, interpre-
tation, validation, storage and dissemination is critical
to ensure proper use. Therefore, it is crucial to devel-
op formats, as well as minimal requirements, to
ensure data quality.
Current genomic and proteomic analytical meth-
ods, while highly developed and powerful, easily
generate gigabyte-sized datasets. Informatics has to
manage this data with respect to retrieval of infor-
mation in a reasonable time and with appropriate
quality. Furthermore, the abundant genomic or pro-
teomic information that accumulated from prior stud-
ies could almost never be used adequately for the
initial planning or interpretation of new experiments
or data from a given study because the integration of
data from outside studies was challenging and tedi-
ous. Therefore, it is not surprising that in every pro-
teomic experiment results are rediscovered (157). The
use of external and remote resources in own research
causes various problems in many cases, as the access
may be difficult and integration of the data retrieved
is tedious or dependent on hardware. Very often, the
compilation of the external information has to be
done manually, and depends on the capabilities of the
individuals involved. Transparency and efforts to
generate the tools to integrate previous data into a
current dataset, and experimental planning, will avoid
redundant and costly studies. As suggested by
Mewes (personal communication, Workshop Clinical
Proteomics, Martinsried 9/2006), it would be prefera-
ble to combine resources with interfaces, using any
desirable programming language, and use these
interfaces to convert generic data formats into stan-
dard formats, send standardized information over the
web, and thereby disseminate standardized and struc-
tured information to any clients via web services. The
Human Proteome Organisation Proteomics Standard
Initiative (HUPO PSI) has begun with these standard-
izing efforts already for proteomic datasets and the
ProDaC consortium (www.fp6-prodac.eu) is develop-
ing practical software tools to produce datasets in
standardized formats. When data generation/analysis
and conversion into standardized file formats is fin-
ished, export from the local database system into a
central data repository like PRIDE (http://www.ebi.
ac.uk/pride) will be obligatory for public datasets as
well as private datasets following the publication of
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results in scientific journals. Such central repositories
will be fundamental in order to avoid rediscovery of
results that are already known.
In ongoing biomarker discovery or clinical studies,
large cohorts of individuals (patients and controls) are
required in order to detect protein patterns that con-
sistently associate with a specific condition and are
distinguishable from the large background of proteins
that randomly fluctuate within the population tested.
The risk of misinterpreting correlating protein pat-
terns as biomarkers is high and should be minimized
where possible. This is particularly the case for a vari-
ety of cancer, but also for other diseases such as type
2 diabetes or heart failure where useful and adequate
diagnostic markers with high-specificity and sensitiv-
ity are lacking, but urgently needed. Therefore, the
success of MS-based discovery of candidate biomar-
kers depends on the ability to properly handle statis-
tical data and interpret results with use of decoy
databases and a defined false discovery rate. The val-
ue of the results obtained and the conclusions that are
drawn can be limited by huge proteomic datasets, the
heterogeneity of patients, sample processing and
data acquisition in multi-centered studies, heteroge-
neity of data formats, processing methods, software
tools and databases involved in the translation of
spectral data into information. Since the beginning,
biomarker discovery has suffered considerably from
inconsistent data acquisition, statistical handling and
validation. Clinical proteomics requires establishment
of SOP and guidelines for specimen, reduction of
complexity, increasing sensitivity of detection, appli-
cation of bioinformatical tools for distribution of
proteomic data into public databases, as well as thor-
ough data generation (158, 159) consistent data anal-
ysis (92), and distinct training and validation of
datasets (160).
These standards include:
Standards and data formats for data acquisition
(raw data), storage (mzXML/mzData) and exchange
(PSI: http://www.psidev.info).
• Public data repositories (Peptide Atlas, PRIDE,
GPMDB, SwissProt/Uniprot)
• Standards for quality assessment (e.g., FDR, com-
posite decoy databases, power analysis)
• Integration towards a ‘‘linear pipeline’’ (Aebersold,
ProDaC)
• Integration of complex databases including biolog-
ical information (systems oriented approach)
When it comes to interpretation of complex data
from clinically oriented studies, it is important to
define rules of conduct for linking clinical phenotypes
with profiling results, and to allow correct statistical
evaluation and interpretation of protein profiles. Stan-
dards for data analysis and quality management have
been established, standards for data reporting
wHUPO-PSI, Molecular Cell Proteomics (MCP) and oth-
er journal guidelinesx have been established, and
databases for proteomics results are being structured
within large HUPO initiatives. For the proteomic com-
munity, search algorithms and a public repository for
peptide identification has been developed (PRIDE:
http://www.ebi.ac.uk/pride).
Data need to be qualified with respect to specificity
for a pathological process. As a basis of proper data
analysis, clustering variables, statistics, reproducibil-
ity, standards and exchange formats and study design
have to be considered carefully. Sample retrieval,
storage and handling are very important parameters
that need to be strictly defined. Furthermore, stan-
dards and protocols need to be established to ensure
reproducibility of the data. Recently established
HUPO standards and SOPs for MS based data acqui-
sition and analysis are considered important step
towards this goal. However, a current challenge that
still remains is heterogeneity of the data heteroge-
neity that might negatively impact integration of pro-
teomics data with other biomedical data.
It is important to allow transparency in the handling
of clinically relevant data by simultaneously ensuring
protection of data and intellectual property. This lim-
itation can only be overcome by teamwork amongst
clinicians, bioinformatics, medical informatics and
proteomic scientists.
Grouped analysis of proteomics data is important
for scientific purposes and for development of effi-
cient therapies. It is essential to use this type of data
to assess therapy-dependent progression of disease
in individual patients in advance, i.e., at diagnosis,
disease relapse or other time points of interest. This
should lead to individualized treatment of patients in
stratified patient groups, and should maximize ther-
apeutic success and minimize adverse drug reactions
(personalized/individualized medicine) (161). The
challenge relates to our ability to reach the right con-
clusions for short-, mid- or long-term therapeutic
approaches, using dynamic proteome patterns that
are influenced by various disease states.
Therefore, clinical proteomics studies need to
include diseased patients as well as healthy or oth-
erwise defined individuals as a reference group. In
addition, an unknown validation set of diseased and
reference individuals, including patients with unrela-
ted diseases will help prove the robustness of classi-
fication for unknown patient samples.
Conclusions
Even though there are a large number of bottlenecks
in fluid proteomics. These include lack of standardi-
zation for specimen processing, quantitation, and
clear strategies for manging biomarkers following
their identification. It is believed that the field holds
great promise. Progress depends on the establish-
ment of SOPs for the selection of patients and speci-
mens, decreasing the complexity of samples to be
analyzed, and the development and use of superior
informatics tools for efficient data management. The
advances in proteomic analysis have made important
improvements in the areas of sample fractionation,
and parameter analysis relating to the fields of affinity
binding technologies, high-resolution liquid phase
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separation methods, as well as for liquid phase tech-
nologies like MS/MS, high-resolution MS-MS and
advances in chemometry and biometry for large-scale
data analysis. These form the basis for high-through-
put and high-content analysis required for clinical
proteomics, and offer the possibility for introducing
these research tools into diagnostic research to
screen for risk factors, identify new disease-specific
or stage-specific biomarkers, and to find novel mark-
ers for therapeutic drug monitoring or new therapeu-
tic targets. Therefore, clinical proteomics has the
potential to complement genomics, metabolomics,
lipidomics, glycomics and transcriptomics, including
splice variant analysis to gain a better understanding
of disease processes. The integration of proteomics
and fluid and cell based technologies will ultimately
lead to a description of the molecular setup of normal
and abnormal cellular and liquid systems within a
relational knowledge system. This will also allow
standardized evaluation of abnormal disease states.
These methods are currently mostly qualitative and
should be regarded as exploratory approaches that
are advancing scientific knowledge within clinical
studies, rather than routine. In the future, this will
gradually change and some of the methods as well
as applications will be established as clinical routine
assays in the clinical laboratory. It is generally accept-
ed that a set of different proteins or peptides (bio-
markers), rather than a single protein or peptide, will
be more efficient in the diagnosis of disease. Individ-
ualized prediction of the course of disease in patients
using characteristic discriminatory data patterns will
permit individualized therapies, identification of new
pharmaceutical targets, and establishment of a stan-
dardized framework of relevant molecular alterations
in disease (162). The control of preanalytical aspects
is most important for clinical proteomics. This is best
met by a high-degree of standardization, including
SOPs, and automated work stations for high-through-
put sample preparation.
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